Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX-629 in frequently relapsing nephrotic syndrome
NCT05599815Phase 2Withdrawn
- Sponsor
- Aldeyra Therapeutics
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of acloproxalap in nephrotic syndrome (3 arms), sponsored by Aldeyra Therapeutics. Primary endpoint: Adverse Event Query. Planned start Jan 2023; status: withdrawn.
02
Drugs
acloproxalap
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT05599815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599815.